Sign in
Taking people in United StatesPhase 4

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

Key facts

Who runs it
VA Office of Research and Development
Where
Birmingham, Seattle, and Tuscaloosa, United StatesSee the 3 sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
70 people, planned
Started
5 Feb 2024
Expected to end
30 Sept 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Methylphenidate
  • Placebo
Record updated
19 August 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Any gender Veteran of the US military
  • Independent decision-making capacity to sign informed consent and Health Insurance Portability and Accountability Act (HIPAA) (i.e., no surrogate consent)
  • Diagnosis of PTSD defined by DSM-5 symptom count on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • CAPS-5 past month total score greater than or equal to 26
  • Subjective neurocognitive impairment, defined as a total score of greater than or equal to 25 (1 standard deviation below the mean) on the NeuroQoL Cognitive Function 8-item self-report form

Who cannot take part

  • Presence of severe psychotic symptoms such that, based on the clinical judgement of the investigator or treatment provider, treatment with an antipsychotic is required
  • Use of any investigational drug, MPH formulation, antipsychotics, mood stabilizers, monoamine oxidase inhibitors, stimulants, atomoxetine, or bupropion within 2 weeks of baseline
  • Treatment with evidence-based trauma-focused therapy for PTSD within 2 weeks of baseline (if participant is receiving therapy, he/she must complete treatment prior to entering study). Supportive psychotherapy may be continued during the study
  • Prior allergic reaction to any MPH formulation
  • Diagnosis of DSM-5-defined bipolar I, schizophrenia spectrum or other psychotic disorders (by MINI)
  • Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 2 months. Patients who utilize alcohol or cannabis but do not meet criteria for moderate or severe disorder are permitted at the discretion of the investigator. Participants must agree to abstain from illicit drugs, including cannabis products containing Tetrahydrocannabinol (THC) even when legal by state law
  • History of severe TBI as defined by the Ohio State University TBI Identification Method
  • Diagnosis of dementia or related progressive neurocognitive disorder, based on clinical records
  • A clinically significant acute or uncontrolled chronic medical/surgical illness that would contraindicate use of MPH, or a known terminal illness
  • Litigating for compensation for a psychiatric disorder outside the Veterans benefits compensation and pension process
  • Increased risk of suicide that necessitates inpatient treatment or treatment excluded by the protocol; and/or intensity of suicidal ideation (Type 4 or Type 5) or any suicidal behavior in the past 2 months on Columbia Suicide Severity Rating Scale (C-SSRS)
  • Pregnancy or lactation, or anticipated pregnancy at any point during study participation. Participants of child-bearing potential must have negative pregnancy test at study entry and must agree to adhere to a medically acceptable method of birth control (e.g., oral, implantable, injectable, or transdermal hormone-based contraceptives; intrauterine device; double-barrier method)
  • Current enrollment in another interventional trial for PTSD

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Birmingham VA Medical Center, Birmingham, ALBirmingham, United StatesContact: Lori Davis, MDTaking people
  • VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Rebekah J Rein, JDTaking people
  • Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, United StatesContact: Lori Davis, MDTaking people

About the trial

What the trial wants to find out

Posttraumatic stress disorder (PTSD) is frequently accompanied by difficulty concentrating, poor memory, and inability to keep up with tasks, which negatively impacts a person's ability to function at work and in relationships. Currently available treatments do not fully relieve all symptoms. A published research report showed positive evidence that the stimulant medication methylphenidate was beneficial in treating these problems. This study will evaluate the ability of methylphenidate to treat PTSD and associated neurocognitive complaints in Veterans. An innovative feature is the study's N-of-1 design. In this design, every participant will move back and forth every 4-5 weeks between treatment with methylphenidate and treatment with placebo, in random order and under double-blind conditions, over a 20-week period. The investigators will compare the aggregated change in PTSD and neurocognitive symptoms between periods of treatment with methylphenidate versus placebo. Results will help clinicians to better choose the best treatment for Veterans living with PTSD.

The 2 groups in the trial

  • N-of-1 crossover study enrollment: start with placeboOther group

    All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).

    Treatment: Methylphenidate and Placebo

  • N-of-1 crossover study enrollment: start with methylphenidateOther group

    All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).

    Treatment: Methylphenidate and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Placebo-Controlled Trial of Methylphenidate for the Treatment of Post-Traumatic Stress Disorder With Associated Neurocognitive Complaints
Criteria questions
Built from NCT05776056, who can take part
Record updated
19 August 2026